Sickle Cell Kidney Sample Bank
Official title: Sickle Cell Kidney (SCeK) Biorepository
Run by University of Texas Southwestern Medical Center · NCT07064174 · Data updated 2026-11-12
This project will collect blood and urine from adults with sickle cell disease or sickle cell trait to see if linked samples and medical records can help researchers learn how kidney disease starts and progresses.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Dallas, Texas and 1 other locations) |
| Status | Recruiting |
| Started | August 22, 2024 |
| Main results expected | December 2049 |
| Study ends | December 2049 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT07064174 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults (18–65 years) with a confirmed hemoglobinopathy (sickle cell disease or trait) and an eGFR ≥15 mL/min, with demographically matched controls without hemoglobinopathy considered selectively.
✕Probably not a fit
People on dialysis or with eGFR <15 mL/min, those 66 or older, active pregnant individuals, those with recent severe sickle pain requiring acute care, active induction cancer treatment, or prisoners are excluded and unlikely to receive direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Chronic kidney disease occurs early and more often in people with sickle cell disease and sickle cell trait, but the underlying causes and risk factors are not well understood. The SCeK Biorepository collects well-annotated blood and urine samples from consenting adults and links those samples to detailed clinical data. Stored samples can be re-tested with new laboratory methods to search for biomarkers, mechanisms, and predictors of kidney disease onset and progression. The repository is maintained by UT Southwestern and Parkland to support future research and development of tailored prevention or treatment strategies.
Why it matters
Potential benefit: If successful, this could identify early markers and biological targets that help prevent or slow kidney disease in people with sickle cell disease or trait.
How similar studies have gone: Other disease-focused biorepositories have successfully produced biomarkers and mechanistic insights, though dedicated kidney-focused collections for sickle cell disease and trait are relatively limited so far.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age over 18 years, 2. Estimated glomerular filtration rate greater than or equal to 15 mL/min, 3. Presence of any hemoglobinopathy (will need to be confirmed by hemoglobin electrophoresis or genetic testing), 4. Controls (absence of hemoglobinopathy) will be subject to review and only selected if demographics are identical to a currently enrolled participant with a hemoglobinopathy. Exclusion Criteria: 1. Age 66 years or older, 2. Estimated glomerular filtration rate less than 15 mL/min or on dialysis, 3. Active pregnancy (may be enrolled 4 weeks or more after delivery), 4. Active sickle cell pain episode requiring hospitalization or emergency room visit or pain infusion clinic visit (may be enrolled 2 weeks or more after resolution of severe pain), 5. Active malignancy on induction or consolidation treatment. Maintenance chemotherapy in remission will be considered, 6. Prisoners.
Where it's running
-
Parkland Memorial Hospital
Dallas, Texas, United States Recruiting -
University of Texas Southwestern Medical Center
Dallas, Texas, United States Recruiting
Study contacts
- Study coordinator: Kabir O Olaniran, MD, MPH, FASN
- Email: SCeK@UTSouthwestern.edu
- Phone: 214-645-8267
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China
This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
Sickle cell disease registry at Ain Shams University
This project creates an Ain Shams University registry of children and young people with sickle cell disease to track their health over time without providing a treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.